Was it failure or an inadequate trial? For a composite man with OCD, the MN663 Unit 8 analysis audits dose, duration, adherence and therapy before ranking three next steps. Searches like "mn 663 unit 8 assignment example", "mn663 unit 8 sample" and "mn663 unit 8 example" land here.
A Failed Trial or an Incomplete One? Treatment Failure Analysis for a 33-Year-Old With Obsessive-Compulsive Disorder
[Student Name]
Purdue University Global
MN663: PMHNP Diagnosis and Management Across the Lifespan I
Unit 8 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. Doses are bracketed; nothing here is a prescribing instruction.
Case Summary
A composite 33-year-old software tester has obsessive-compulsive disorder with contamination fears and checking rituals that take about three hours a day. He washes his hands until they crack and checks the stove and locks repeatedly before leaving home, often arriving late to work. He has been written up once for lateness and fears losing his job, which is part of why he sought treatment. He started sertraline twelve weeks ago. His Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score was 29 at baseline and is 26 now. He was referred for exposure and response prevention at intake and has been on the therapy waitlist since.
Part 1: Auditing the Trial
Question 1: was the medicine taken? Pharmacy refill records show on-time refills for all twelve weeks, and he reports missing no more than one dose a week. Verdict: met.
Question 2: was the dose adequate for OCD? Obsessive-compulsive disorder often requires higher SSRI doses than depression. His dose was increased to [a moderate step] at week 4 and has stayed there, below the upper range commonly used in OCD. Verdict: not met.
Question 3: was the duration long enough at an adequate dose? An adequate SSRI trial in OCD generally means 8 to 12 weeks, with several of those weeks at the maximum tolerated dose. He has had twelve weeks in total but only eight at his current dose, and that dose was not maximal. Verdict: not met.
Question 4: was exposure and response prevention offered alongside the medicine? He was referred but has not started because of the waitlist. Verdict: not met.
Part 2: Scoring the Response
His Y-BOCS fell from 29 to 26, a reduction of about 10 percent. An international expert consensus defines treatment response in OCD as a reduction of at least 35 percent and partial response as a reduction of 25 to 35 percent (Mataix-Cols et al., 2016). By those definitions he has not reached even partial response. But because the dose, duration and therapy components of the trial were all incomplete, the finding is better described as an inadequate trial than as a failed one.
Why the Distinction Matters
Calling this a failed trial would lead to one of two moves: adding a second drug or switching to another. Both carry costs. Augmentation with an antipsychotic exposes him to metabolic and other side effects, and switching restarts the clock on a new medication, adding another eight to twelve weeks before its effect can be judged. If the underlying problem is that the first drug was never given at an adequate dose for long enough, and that the most effective psychological treatment was never delivered, then both moves would be premature. The audit protects him from escalating treatment to solve a problem that a complete trial of the current treatment might solve.
Part 3: Ranking the Next Steps
First: optimize the SSRI and start exposure and response prevention together. The audit found that the dose and duration fell short, so the first step is to raise sertraline toward the higher range used in OCD, as tolerated, and continue it for at least another eight weeks at that dose. At the same time, the waitlist problem is addressed directly, through a therapist in a neighboring practice or an intensive program, because ERP is the psychological treatment with the strongest evidence in OCD. In a randomized trial of adults who remained symptomatic on an SSRI, adding ERP produced a greater improvement than adding risperidone or placebo (Simpson et al., 2013). Cost: time and effort from him, including anxiety during exposures, and possible dose-related side effects.
Second: antipsychotic augmentation. If he remains symptomatic after an adequate SSRI trial with ERP, adding a low dose of an antipsychotic such as risperidone or aripiprazole is supported by meta-analysis, with about a third of patients responding (Bloch et al., 2006). Cost: weight gain, metabolic effects and sedation, with modest benefit.
Third: a switch to a different SSRI or to clomipramine. A switch comes last because the current SSRI has not yet been given a fair trial; switching now would discard a drug that may still work at an adequate dose. Clomipramine has strong evidence in OCD but more side effects and toxicity in overdose.
Addressing the Waitlist
The absence of exposure and response prevention is the largest gap in his care so far. The local waitlist is about four more months. Three alternatives were found: a therapist trained in ERP at a practice twenty minutes away with openings next month, an intensive outpatient OCD program in the nearest city offering three sessions a week for six weeks, and therapist-guided online ERP through a program his insurance covers. He chose the practice nearby, with the online program kept as a fallback. Starting ERP within a month turns the next step from a medication-only change into the combined treatment the evidence supports.
Talking With Him
He was frustrated that twelve weeks had brought so little change and asked whether he was "one of the people it doesn't work for." He was told honestly that the trial had not yet been a full one, that many people with OCD need higher doses and more time than people with depression, and that ERP adds substantially to medication. He was also told what raising the dose might bring, such as nausea, sleep changes or sexual side effects, and that these can be discussed and managed rather than simply endured or kept to himself.
Plan and Measurement
Raise sertraline toward [a higher composite step] over the next four weeks as tolerated. Contact the neighboring practice about an ERP opening this month. Repeat the Y-BOCS every four weeks. Reassess at twelve weeks after reaching the new dose, with at least six weeks of ERP completed. If his Y-BOCS has not fallen by at least 25 percent by then, move to the second option. Between visits, he will keep a brief daily record of time spent washing and checking, which gives a second measure alongside the Y-BOCS and lets him see small changes that a monthly score might hide. Suicidal thoughts and mood will be asked about at every visit, since depression commonly accompanies OCD and can emerge or worsen when symptoms persist.
References
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V., Bracken, M. B., & Leckman, J. F. (2006). A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry, 11(7), 622-632. https://doi.org/10.1038/sj.mp.4001823
Mataix-Cols, D., Fernández de la Cruz, L., Nordsletten, A. E., Lenhard, F., Isomura, K., & Simpson, H. B. (2016). Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. World Psychiatry, 15(1), 80-81. https://doi.org/10.1002/wps.20299
Simpson, H. B., Foa, E. B., Liebowitz, M. R., Huppert, J. D., Cahill, S., Maher, M. J., McLean, C. P., Bender, J., Marcus, S. M., Williams, M. T., Weaver, J., Vermes, D., Van Meter, P. E., Rodriguez, C. I., Powers, M., Pinto, A., Imms, P., Hahn, C., & Campeas, R. (2013). Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: A randomized clinical trial. JAMA Psychiatry, 70(11), 1190-1199. https://doi.org/10.1001/jamapsychiatry.2013.1932
How this MN663 Unit 8 example is structured
Audit precedes response, because a response figure means little until the trial behind it has been shown adequate. Each audit question receives a finding from the case and a verdict: met, not met or uncertain. Only then does the paper interpret the score change, placing it against published definitions rather than impression. The ranking of next steps is justified row by row. Optimizing first is argued from the finding that dose and duration fell short, which reframes the episode as an incomplete trial more than a failed one. ERP is paired with optimization rather than deferred, citing Simpson and colleagues (2013), whose trial found ERP augmentation outperformed risperidone augmentation in adults still symptomatic on an SSRI. Antipsychotic augmentation follows as the second option, citing the Bloch et al. (2006) meta-analysis. A switch comes last, with the reason for its place stated.
Get an MN663 Unit 8 example written to your instructions
For Unit 8, send the case your MN663 section posted with every detail of the first trial, the dose steps, weeks at each and any therapy, plus the rubric. The free first analysis audits that trial before judging it, ranks next steps by evidence and attaches an exit condition to each; it reaches you within 24-48h. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
MN663 Unit 8 questions, answered
How long must a trial last before it counts as failed?
That depends on the disorder and the dose reached. Depression trials are usually judged after several weeks at an adequate dose, while OCD commonly needs longer, often eight to twelve weeks with a substantial part at a higher dose. Name the standard the paper applies, cite it, and show whether the case meets it before using the word failure.
Is switching or augmenting the better next step?
Neither wins in every case. Augmenting keeps whatever benefit the first drug gave, while switching avoids adding side effects and interactions. The evidence differs by disorder and by what is added. Let the case decide it: how large any response was, how well the drug was tolerated and what the patient prefers, with trial evidence cited for the direction taken.
Should the analysis revisit the diagnosis?
Briefly, yes. A trial can look like it failed because the diagnosis was incomplete, for instance when tics, hoarding, depression or substance use accompany the main disorder. A short paragraph confirming the diagnosis, or naming what would change it, strengthens the analysis without turning it into a new differential.